These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 35180141)
1. Serological cancer-associated protein biomarker levels at bowel endoscopy: Increased risk of subsequent primary malignancy. Piper TB; Nielsen HJ; Christensen IJ Tumour Biol; 2022; 44(1):1-16. PubMed ID: 35180141 [TBL] [Abstract][Full Text] [Related]
2. Increased serological, cancer-associated protein biomarker levels at diagnosis of large bowel adenoma: Risk of subsequent primary malignancy? Piper TB; Jørgensen LN; Olsen J; Nielsen KT; Davis G; Johansen JS; Jarle Christensen I; Nielsen HJ Acta Oncol; 2019; 58(sup1):S42-S48. PubMed ID: 30523734 [TBL] [Abstract][Full Text] [Related]
3. Increased serological cancer-associated biomarker levels at large bowel endoscopy and risk of subsequent primary cancer (†). Hvolris MH; Piper TB; Hammer E; Jørgensen LN; Olsen J; Rahr HB; Nielsen KT; Laurberg S; Christensen IJ; Brünner N; Johansen JS; Davis GJ; Dowell BL; Nielsen HJ Scand J Gastroenterol; 2016 Jul; 51(7):860-5. PubMed ID: 26918701 [TBL] [Abstract][Full Text] [Related]
4. Plasma TIMP-1 and CEA as Markers for Detection of Primary Colorectal Cancer: A Prospective Validation Study Including Symptomatic and Non-symptomatic Individuals. Christensen IJ; Brünner N; Dowell B; Davis G; Nielsen HJ; Newstead G; King D Anticancer Res; 2015 Sep; 35(9):4935-41. PubMed ID: 26254391 [TBL] [Abstract][Full Text] [Related]
5. Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals. Nielsen HJ; Brünner N; Jorgensen LN; Olsen J; Rahr HB; Thygesen K; Hoyer U; Laurberg S; Stieber P; Blankenstein MA; Davis G; Dowell BL; Christensen IJ; ; Scand J Gastroenterol; 2011 Jan; 46(1):60-9. PubMed ID: 20799911 [TBL] [Abstract][Full Text] [Related]
6. CA125: A superior prognostic biomarker for colorectal cancer compared to CEA, CA19-9 or CA242. Björkman K; Mustonen H; Kaprio T; Kekki H; Pettersson K; Haglund C; Böckelman C Tumour Biol; 2021; 43(1):57-70. PubMed ID: 33935125 [TBL] [Abstract][Full Text] [Related]
7. Blood-based Biomarkers at Large Bowel Endoscopy and Prediction of Future Malignancies. Kring TS; Piper TB; Jørgensen LN; Olsen J; Rahr HB; Nielsen KT; Laurberg S; Davis G; Dowell B; Johansen JS; Christensen IJ; Brünner N; Nielsen HJ Biomark Cancer; 2015; 7():57-61. PubMed ID: 26526637 [TBL] [Abstract][Full Text] [Related]
8. Diagnostic values of MMP-7, MMP-9, MMP-11, TIMP-1, TIMP-2, CEA, and CA19-9 in patients with colorectal cancer. Huang X; Lan Y; Li E; Li J; Deng Q; Deng X J Int Med Res; 2021 May; 49(5):3000605211012570. PubMed ID: 33942633 [TBL] [Abstract][Full Text] [Related]
9. The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients. Mroczko B; Groblewska M; Okulczyk B; Kedra B; Szmitkowski M Int J Colorectal Dis; 2010 Oct; 25(10):1177-84. PubMed ID: 20556397 [TBL] [Abstract][Full Text] [Related]
10. A novel prognostic index in colorectal cancer defined by serum carcinoembryonic antigen and plasma tissue inhibitor of metalloproteinases-1. Nielsen HJ; Christensen IJ; Brünner N Scand J Gastroenterol; 2010; 45(2):200-7. PubMed ID: 20095885 [TBL] [Abstract][Full Text] [Related]
11. Elevated serum YKL-40, IL-6, CRP, CEA, and CA19-9 combined as a prognostic biomarker panel after resection of colorectal liver metastases. Peltonen R; Gramkow MH; Dehlendorff C; Osterlund PJ; Johansen JS; Isoniemi H PLoS One; 2020; 15(8):e0236569. PubMed ID: 32756596 [TBL] [Abstract][Full Text] [Related]
12. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients. Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815 [TBL] [Abstract][Full Text] [Related]
13. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer. Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838 [TBL] [Abstract][Full Text] [Related]
14. Should a colonoscopy be recommended for healthy individuals with increased carcinoembryonic antigen levels? A case-control study. Lee JH; Hong SP; Jeon TJ; Kang GH; Choi WC; Jeon SM; Moon CM; Park JJ; Cheon JH; Kim TI; Kim WH Dig Dis Sci; 2011 Aug; 56(8):2396-403. PubMed ID: 21327920 [TBL] [Abstract][Full Text] [Related]
15. Development of blood-based biomarker tests for early detection of colorectal neoplasia: Influence of blood collection timing and handling procedures. Lech Pedersen N; Mertz Petersen M; Ladd JJ; Lampe PD; Bresalier RS; Davis GJ; Demuth C; Jensen SØ; Andersen CL; Ferm L; Christensen IJ; Nielsen HJ Clin Chim Acta; 2020 Aug; 507():39-53. PubMed ID: 32272156 [TBL] [Abstract][Full Text] [Related]
16. Plasma circular RNA panel acts as a novel diagnostic biomarker for colorectal cancer. Lin J; Cai D; Li W; Yu T; Mao H; Jiang S; Xiao B Clin Biochem; 2019 Dec; 74():60-68. PubMed ID: 31669510 [TBL] [Abstract][Full Text] [Related]
17. TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Sørensen NM; Byström P; Christensen IJ; Berglund A; Nielsen HJ; Brünner N; Glimelius B Clin Cancer Res; 2007 Jul; 13(14):4117-22. PubMed ID: 17634538 [TBL] [Abstract][Full Text] [Related]
18. Detection of colorectal neoplasia: Combination of eight blood-based, cancer-associated protein biomarkers. Wilhelmsen M; Christensen IJ; Rasmussen L; Jørgensen LN; Madsen MR; Vilandt J; Hillig T; Klaerke M; Nielsen KT; Laurberg S; Brünner N; Gawel S; Yang X; Davis G; Heijboer A; Martens F; Nielsen HJ Int J Cancer; 2017 Mar; 140(6):1436-1446. PubMed ID: 27935033 [TBL] [Abstract][Full Text] [Related]
19. Serum YKL-40 in risk assessment for colorectal cancer: a prospective study of 4,496 subjects at risk of colorectal cancer. Johansen JS; Christensen IJ; Jørgensen LN; Olsen J; Rahr HB; Nielsen KT; Laurberg S; Brünner N; Nielsen HJ Cancer Epidemiol Biomarkers Prev; 2015 Mar; 24(3):621-6. PubMed ID: 25597749 [TBL] [Abstract][Full Text] [Related]
20. Serum Cyr61 as a potential biomarker for diagnosis of colorectal cancer. Song YF; Xu ZB; Zhu XJ; Tao X; Liu JL; Gao FL; Wu CL; Song B; Lin Q Clin Transl Oncol; 2017 Apr; 19(4):519-524. PubMed ID: 27743169 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]